{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:34:21Z","timestamp":1790775261357,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>An excessive immune response known as cytokine storm is the hallmark of severe COVID-19. The cause of this cytokine rampage is yet not known. Based on recent epidemiological evidence, we hypothesized that CD80\/86 signaling is essential for this hyperinflammation, and that blocking this proinflammatory axis could be an effective therapeutic approach to protect against severe COVID-19. Here we provide exploratory evidence that abatacept, a drug that blocks CD80\/86 co-stimulation, produces changes at the systemic level that are highly antagonistic of the proinflammatory processes elicited by COVID-19. Using RNA-seq from blood samples from a longitudinal cohort of n\u2009=\u200938 rheumatic patients treated with abatacept, we determined the immunological processes that are significantly regulated by this treatment. We then analyzed available blood RNA-seq from two COVID19 patient cohorts, a very early cohort from the epicenter of the pandemic in China (n\u2009=\u20093 COVID-19 cases and n\u2009=\u20093 controls), and a recent and larger cohort from the USA (n\u2009=\u200949 severe and n\u2009=\u200951 mild COVD-19 patients). We found a highly significant antagonism between SARS-CoV-2 infection and COVID-19 severity with the systemic response to abatacept. Analysis of previous single-cell RNA-seq data from bronchoalveolar lavage fluid from mild and severe COVID-19 patients and controls, reinforce the implication of the CD80\/86 proinflammatory axis. Our functional results further support abatacept as a candidate therapeutic approach to prevent severe COVID-19.<\/jats:p>","DOI":"10.1038\/s41598-021-90797-0","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T11:32:54Z","timestamp":1622547174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Targeting of the CD80\/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19"],"prefix":"10.1038","volume":"11","author":[{"given":"Antonio","family":"Juli\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bonafonte-Pard\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"L\u00f3pez-Lasanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"L\u00f3pez-Corbeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio H.","family":"Mart\u00ednez-Mateu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Llad\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Rodr\u00edguez-Nunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Marsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"90797_CR1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323, 1239\u20131242 (2020).","journal-title":"JAMA"},{"key":"90797_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41591-019-0740-8","volume":"26","author":"JT Wu","year":"2020","unstructured":"Wu, J. T. et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat. Med. 26, 1\u20135 (2020).","journal-title":"Nat. Med."},{"key":"90797_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"BJB Moore","year":"2020","unstructured":"Moore, B. J. B. & June, C. H. Cytokine release syndrome in severe COVID-19. Science (New York) 368, 473 (2020).","journal-title":"Science (New York)"},{"key":"90797_CR4","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S2213-2600(20)30110-7","volume":"8","author":"SA \u00d1amendys-Silva","year":"2020","unstructured":"\u00d1amendys-Silva, S. A. Respiratory support for patients with COVID-19 infection. Lancet Respir. Med. 8, e18 (2020).","journal-title":"Lancet Respir. Med."},{"key":"90797_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41577-019-0258-9","volume":"20","author":"M Merad","year":"2020","unstructured":"Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nat. Rev. Immunol. 20, 1\u20138 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"90797_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.semarthrit.2020.05.001","volume":"50","author":"X Michelena","year":"2020","unstructured":"Michelena, X. et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin. Arthritis Rheum. 50, 564\u2013570 (2020).","journal-title":"Semin. Arthritis Rheum."},{"key":"90797_CR7","first-page":"1","volume":"46","author":"Q Ruan","year":"2020","unstructured":"Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China. Intens. Care Med. 46, 1\u20133 (2020).","journal-title":"China. Intens. Care Med."},{"key":"90797_CR8","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.08.029769","author":"C Guo","year":"2020","unstructured":"Guo, C. et al. Tocilizumab treatment in severe COVID-19 patients attenuates the inflammatory storm incited by monocyte centric immune interactions revealed by single-cell analysis. BioRxiv. https:\/\/doi.org\/10.1101\/2020.04.08.029769 (2020).","journal-title":"BioRxiv."},{"key":"90797_CR9","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor \u03b1 inhibition. N. Engl. J. Med. 353, 1114\u20131123 (2005).","journal-title":"N. Engl. J. Med."},{"key":"90797_CR10","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.23.20026690","author":"M Liao","year":"2020","unstructured":"Liao, M. et al. The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. MedRxiv. https:\/\/doi.org\/10.1101\/2020.02.23.20026690 (2020).","journal-title":"MedRxiv."},{"key":"90797_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-020-0901-9","volume":"26","author":"M Liao","year":"2020","unstructured":"Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 26, 1\u20133 (2020).","journal-title":"Nat. Med."},{"key":"90797_CR12","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1126\/science.abc8511","volume":"369","author":"D Mathew","year":"2020","unstructured":"Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369, 1203 (2020).","journal-title":"Science"},{"key":"90797_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/22221751.2020.1747363","volume":"9","author":"Y Xiong","year":"2020","unstructured":"Xiong, Y. et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg. Microbes Infect. 9, 761\u2013770 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"90797_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cels.2020.10.003","volume":"12","author":"KA Overmyer","year":"2020","unstructured":"Overmyer, K. A. et al. Large-scale multi-omic analysis of COVID-19 severity. Cell Syst. 12, 23\u201340 (2020).","journal-title":"Cell Syst."},{"key":"90797_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/ni.3052","volume":"16","author":"M Kopf","year":"2015","unstructured":"Kopf, M., Schneider, C. & Nobs, S. P. The development and function of lung-resident macrophages and dendritic cells. Nat. Immunol. 16, 36 (2015).","journal-title":"Nat. Immunol."},{"key":"90797_CR16","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501 (2020).","journal-title":"Cell"},{"key":"90797_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta, P. et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033\u20131034 (2020).","journal-title":"Lancet"},{"key":"90797_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"90797_CR19","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","volume":"52","author":"N Vabret","year":"2020","unstructured":"Vabret, N. et al. Immunology of COVID-19: Current state of the science. Immunity 52, 910\u2013941 (2020).","journal-title":"Immunity"},{"key":"90797_CR20","first-page":"020","volume":"3","author":"J Gong","year":"2020","unstructured":"Gong, J. et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia. MedRxiv 3, 020 (2020).","journal-title":"MedRxiv"},{"key":"90797_CR21","first-page":"777","volume":"25","author":"T Gao","year":"2020","unstructured":"Gao, T. et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. MedRxiv 25, 777 (2020).","journal-title":"MedRxiv"},{"key":"90797_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jmv.20499","volume":"78","author":"L Zhang","year":"2006","unstructured":"Zhang, L. et al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J. Med. Virol. 78, 1\u20138 (2006).","journal-title":"J. Med. Virol."},{"key":"90797_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","volume":"451","author":"S-F Wang","year":"2014","unstructured":"Wang, S.-F. et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem. Biophys. Res. Commun. 451, 208\u2013214 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"90797_CR24","doi-asserted-by":"publisher","first-page":"10582","DOI":"10.1128\/JVI.00671-11","volume":"85","author":"M Jaume","year":"2011","unstructured":"Jaume, M. et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent Fc\u03b3R pathway. J. Virol. 85, 10582\u201310597 (2011).","journal-title":"J. Virol."},{"key":"90797_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123158","author":"L Liu","year":"2019","unstructured":"Liu, L. et al. Anti\u2013spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI iIsight. https:\/\/doi.org\/10.1172\/jci.insight.123158 (2019).","journal-title":"JCI insight."},{"key":"90797_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41577-020-0321-6","volume":"20","author":"A Iwasaki","year":"2020","unstructured":"Iwasaki, A. & Yang, Y. The potential danger of suboptimal antibody responses in COVID-19. Nat. Rev. Immunol. 20, 1\u20133 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"90797_CR27","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"WS Lee","year":"2020","unstructured":"Lee, W. S., Wheatley, A. K., Kent, S. J. & DeKosky, B. J. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat. Microbiol. 5, 1185\u20131191 (2020).","journal-title":"Nat. Microbiol."},{"key":"90797_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","volume":"584","author":"C Lucas","year":"2020","unstructured":"Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463\u2013469 (2020).","journal-title":"Nature"},{"key":"90797_CR29","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen, J. S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 371, 987\u2013997 (2008).","journal-title":"Lancet"},{"key":"90797_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","volume":"48","author":"C Fern\u00e1ndez-Diaz","year":"2018","unstructured":"Fern\u00e1ndez-Diaz, C. et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Semin. Arthritis Rheum. 48, 22\u201327 (2018).","journal-title":"Semin. Arthritis Rheum."},{"key":"90797_CR31","doi-asserted-by":"publisher","first-page":"6794","DOI":"10.4049\/jimmunol.163.12.6794","volume":"163","author":"E Isra\u00ebl-Assayag","year":"1999","unstructured":"Isra\u00ebl-Assayag, E., Fournier, M. & Cormier, Y. Blockade of T cell costimulation by CTLA4-Ig inhibits lung inflammation in murine hypersensitivity pneumonitis. J. Immunol. 163, 6794\u20136799 (1999).","journal-title":"J. Immunol."},{"key":"90797_CR32","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.healun.2004.07.011","volume":"24","author":"LP Nicod","year":"2005","unstructured":"Nicod, L. P., Joudrier, S., Isler, P., Spiliopoulos, A. & Pache, J.-C. Upregulation of CD40, CD80, CD83 or CD86 on alveolar macrophages after lung transplantation. J. Hear. Lung Transplant. 24, 1067\u20131075 (2005).","journal-title":"J. Hear. Lung Transplant."},{"key":"90797_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cyto.2018.01.016","volume":"107","author":"D Parker","year":"2018","unstructured":"Parker, D. CD80\/CD86 signaling contributes to the proinflammatory response of Staphylococcus aureus in the airway. Cytokine 107, 130\u2013136 (2018).","journal-title":"Cytokine"},{"key":"90797_CR34","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.semarthrit.2019.01.009","volume":"48","author":"F Montastruc","year":"2019","unstructured":"Montastruc, F. et al. Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study. Semin. Arthritis Rheum. 48, 1053\u20131058 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"90797_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/acr.23824","volume":"72","author":"SK Chen","year":"2020","unstructured":"Chen, S. K., Liao, K. P., Liu, J. & Kim, S. C. Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: A propensity score\u2014Matched Cohort Study. Arthritis Care Res. (Hoboken) 72, 9\u201317 (2020).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"90797_CR36","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.autrev.2013.06.011","volume":"12","author":"F Atzeni","year":"2013","unstructured":"Atzeni, F. et al. Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmun. Rev. 12, 1115\u20131117 (2013).","journal-title":"Autoimmun. Rev."},{"key":"90797_CR37","first-page":"1639","volume":"78","author":"R Alten","year":"2019","unstructured":"Alten, R. et al. ASCORE, a 2-year, observational, prospective multicentre study of subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice: 1-year interim analysis. BMJ J. 78, 1639 (2019).","journal-title":"BMJ J."},{"key":"90797_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"90797_CR39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1186\/s12864-018-4933-1","volume":"19","author":"Y Fu","year":"2018","unstructured":"Fu, Y., Wu, P.-H., Beane, T., Zamore, P. D. & Weng, Z. Elimination of PCR duplicates in RNA-seq and small RNA-seq using unique molecular identifiers. BMC Genomics 19, 531 (2018).","journal-title":"BMC Genomics"},{"key":"90797_CR40","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The sequence alignment\/map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"90797_CR41","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"90797_CR42","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"90797_CR43","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).","journal-title":"Genome Biol."},{"key":"90797_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-020-03576-5","volume":"21","author":"R Aguirre-Gamboa","year":"2020","unstructured":"Aguirre-Gamboa, R. et al. Deconvolution of bulk blood eQTL effects into immune cell subpopulations. BMC Bioinform. 21, 1\u201323 (2020).","journal-title":"BMC Bioinform."},{"key":"90797_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"90797_CR46","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"90797_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"KJ Dkebski","year":"2016","unstructured":"Dkebski, K. J. et al. Etiology matters\u2014Genomic DNA methylation patterns in three rat models of acquired epilepsy. Sci. Rep. 6, 1\u201314 (2016).","journal-title":"Sci. Rep."},{"key":"90797_CR48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"90797_CR49","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","volume":"27","author":"Y Shi","year":"2020","unstructured":"Shi, Y. et al. COVID-19 infection: The perspectives on immune responses. Cell Death Differ. 27, 1451\u20131454 (2020).","journal-title":"Cell Death Differ."},{"key":"90797_CR50","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/bjh.16749","volume":"189","author":"H Fogarty","year":"2020","unstructured":"Fogarty, H. et al. COVID-19 coagulopathy in Caucasian patients. Br. J. Haematol. 189, 1044\u20131049 (2020).","journal-title":"Br. J. Haematol."},{"key":"90797_CR51","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"90797_CR52","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902 (2019).","journal-title":"Cell"},{"key":"90797_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-019-1874-1","volume":"20","author":"C Hafemeister","year":"2019","unstructured":"Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 1\u201315 (2019).","journal-title":"Genome Biol."},{"key":"90797_CR54","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nri1349","volume":"4","author":"L Chen","year":"2004","unstructured":"Chen, L. Co-inhibitory molecules of the B7\u2013CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4, 336\u2013347 (2004).","journal-title":"Nat. Rev. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90797-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90797-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90797-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T19:42:42Z","timestamp":1725133362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90797-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["90797"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-90797-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"assertion":[{"value":"28 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SM and RMM are co-founders of IMIDomics, a biotech company in precision medicine for immune-mediated inflammatory diseases. AJ is also affiliated with IMIDomics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11462"}}